ArticleBMC cardiovascular disorders2026
Stress hyperglycemia ratio improves 28-day mortality prediction beyond GRACE score in critically ill patients with acute coronary syndrome: a retrospective cohort study from MIMIC-IV.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe stress hyperglycemia ratio (SHR) is increasingly recognized as a reliable biomarker for adverse outcomes. However, its prognostic value specifically for the standardized endpoint of 28-day mortality in critically ill patients with ACS, and whether it provides incremental predictive power over the Global Registry of Acute Coronary Events (GRACE) score, remains unclear.
methodsThis retrospective cohort study analyzed 2,763 critically ill ACS patients from the MIMIC-IV database. Multivariable Cox regression evaluated the association between SHR and 28-day mortality. RCSs were used to assess the dose-response relationship. The incremental value of adding SHR to the GRACE score was quantified by the AUC, NRI, and IDI. Machine learning algorithms with SHAP interpretation were employed for complementary validation.
resultsElevated SHR was independently associated with increased 28-day mortality (adjusted HR 1.60, 95% CI: 1.30-1.96, P < 0.001) after adjustment for confounders. Spline analysis revealed a continuous linear relationship. Integrating SHR yielded an improvement in the predictive discrimination of the GRACE score (AUC increased from 0.796 to 0.816, P < 0.001). More importantly, it optimized risk stratification, as evidenced by significant improvements in reclassification metrics (NRI 0.037, IDI 0.023; both P < 0.001). Machine learning analysis ranked SHR among the top 10 predictors.
conclusionsSHR serves as an independent predictor of 28-day mortality in critically ill ACS patients. By providing incremental prognostic value to the GRACE score, SHR facilitates refined risk stratification, offering a practical and accessible tool for the early identification of high-risk individuals in the ICU.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.